Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Veracyte, Inc.

35 indications, side-by-side phase, drug & LoA

$47.33

-0.09 (-0.19%)

C 48Pipeline Score Diagnostics · Commercial
Market Cap
3.59 B
EPS
1.11
P/E Ratio
41.45 $
Value Trade
70.63 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    139.07 M

  • R&D Expenses

    27.10 M

  • Operating CF

    35.22 M

  • Total Assets

    1.44 B

  • Total Liabilities

    91.99 M

  • Equity

    1.34 B

  • D/E Ratio

    12,345

17.97 %
Week
33.26 %
1 Month
24.63 %
3 Month
9.72 %
6 Month
18.59 %
5 Year
246.38 %
All Time
Cash Data
Profitable

  • Cash Position

    263.14 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 6, 2026
Overview
Volume
1.08 M
52 Week Range
22.61 - 50.71
% held by Insiders
2.65 %
% held by Institutions
110.47 %
Enterprise Value
3.19 B
Total Shares
79.03 M
Short %
9.44 %
Float Shares
77.93 M
Company Description
HQ: 6000 SHORELINE COURT, SUITE 30...
Employees:755
https://www.veracyte.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C48
Pipeline Score
$1.1B
Pipeline Value
Valuation Signal
2
Drugs Scored
1.0x
rNPV / MCap
Top 68%
Small Cap
(rank 291 of 905)
Percentile Rank
Veracyte, Inc. carries a moderate pipeline score (48/100), with $1.7B risk-adjusted pipeline value, led by Darolutamide in Prostate Cancer (Phase 2), across $181B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Darolutamide
Small molecule		Prostate CancerPhase 2NCT0402537219% $1.1B ACTIVE NOT_RECRUITING 727 - -Mar 1, 2028ELEVATED_RISKLOW
May 24, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Percepta Nasal Swab
lung cancer,lung nodules
Phase 2
2025-08-26
Percepta Nasal Swab
lung cancer,lung nodules
Phase 2
2025-08-26
Percepta Nasal Swab
lung cancer,lung nodules
Phase 2
2025-08-26
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in VCYT
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
VCYT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VCYT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VCYT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
VCYT Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
VCYT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Veracyte, Inc. (VCYT) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How VCYT ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Sarcoma #8 of 31 PHASE 3 Tislelizumab
NVS INTS LLY
$1.75B 0.8 FOLLOWER
Pancreatic Cancer #14 of 73 PHASE 3 Tislelizumab
RVMD RCUS AZN
$3.7B 0.8 FOLLOWER
Prostate Cancer #15 of 53 PHASE 2 Darolutamide + Zoladex + Zoladex LA + Decapeptyl sustained release + Depo-Eligard + Firmagon + Docetaxel
MRK AZN PFE
$25.12B 0.77 FOLLOWER
Colorectal Cancer #20 of 82 PHASE 3 Tislelizumab
ABBV BMY MRK
$7.68B 0.8 FOLLOWER
Lung Cancer #22 of 79 PHASE 3 Tislelizumab
MRK GILD AMGN
$28.1B 0.85 CONTENDER